VivoSeq
Other

Adiposity

0

Pipeline Programs↗

1

Active Trials↗

0

Companies Involved↗

Adiposity is an early-stage landscape with 0 programs across 0 companies.

Intelligence

Pipeline Metrics

Competitive Density

6/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

83/100

Attrition Rate

14/100

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

7

clinical trials

Completed5 · 71%
Terminated1 · 14%
Active, not recruiting1 · 14%

Clinical Trials

Trial Activity

7 trials

Adiposity and Endothelin Receptor Function
Active, not recruiting·—·Phase 1·NCT03583866·25 enrolled
Rosuvastatin in Visceral Adiposity
Completed·GGöteborg University·Phase 3·NCT01068626·54 enrolled
Visceral Adiposity and Diabetes: Translating Form to Function Using Imaging
Completed·UUniversity of Texas Southwestern Medical Center·Phase 4·NCT02833415·40 enrolled
The Visceral Adiposity Measurement and Observation Study
Completed·TTheratechnologies·N/A·NCT05383456·196 enrolled
Ethnic Differences in the Role of Adipose Tissue Dysfunction in the Development of Type 2 Diabetes
Completed·University of Roehampton·N/A·NCT07666321·39 enrolled
Prospective, Mono-center, Randomized, Single-blinded, Controlled Study on the Performance of Symmcora® Mid-term Suture Versus Novosyn® Suture in Patients Undergoing Robotic Assisted Gastric Bypass Surgery
Completed·AAesculap AG·N/A·NCT05433688·150 enrolled
Effect of Fish Oil on Adiposity and Atherogenic Factors in Type 2 Diabetic Women
Terminated·AAssistance Publique - Hôpitaux de Paris·N/A·NCT00371982·24 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)